Jefferies raises Cogent Biosciences (COGT) price target to $28, maintains Buy rating after strong results from SUMMIT trial for non-AdvSM, showing statistically significant benefits of bezuclastinib over placebo.

Data reveals -8.91 reduction in Total Symptom Score, 57% better than Ayvakit. Safety results positive with 5.9% Grade 3 AST/ALT elevations, down from 10%. Market opportunity estimated at $1 billion for bezuclastinib in ISM, with potential in ASM and GIST.

Cogent Biosciences focuses on precision therapies for genetically defined diseases, with potential for market growth. Consider AI stocks for greater upside potential and less downside risk. For more information on undervalued AI stocks, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating